#1 Clinical Trials Search in Europe

Elotuzumab

Elotuzumab is an innovative drug being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. These trials aim to evaluate the safety and effectiveness of elotuzumab alone or in combination with other drugs in patients with relapsed or refractory multiple myeloma. The research explores various dosing regimens and combination therapies to improve outcomes for patients who have limited treatment options.

Table of Contents

What is Elotuzumab?

Elotuzumab is a medication used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It is known by several names, including Empliciti™, BMS-901608, and HuLuc63[1]. Elotuzumab is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that mimics the immune system’s ability to fight harmful cells[2].

How Elotuzumab Works

Elotuzumab works by targeting a specific protein called SLAMF7, which is found on the surface of myeloma cells and natural killer (NK) cells. By binding to this protein, elotuzumab helps to enhance the ability of NK cells to recognize and kill myeloma cells. This process is known as antibody-dependent cell-mediated cytotoxicity (ADCC)[3]. In simpler terms, elotuzumab helps your immune system to better identify and destroy cancer cells.

Conditions Treated

Elotuzumab is primarily used to treat multiple myeloma, particularly in cases where the disease has returned or has not responded to previous treatments. This is known as relapsed or refractory multiple myeloma[4]. It’s often used in patients who have already tried other treatments, including those who have received prior anti-CD38 antibody therapy[4].

How Elotuzumab is Administered

Elotuzumab is typically given as an intravenous (IV) infusion, which means it’s administered directly into your bloodstream through a vein. The dosage and frequency can vary depending on the specific treatment plan, but a common schedule is:

  • 10 mg/kg weekly (on days 1, 8, 15, and 22) for the first two 28-day cycles
  • 20 mg/kg every 4 weeks (on day 1) for subsequent cycles[1]

Before receiving elotuzumab, you’ll usually be given pre-medications to help prevent potential infusion reactions. These may include:

  • An antihistamine (like diphenhydramine)
  • A histamine-2 blocker (like ranitidine)
  • Acetaminophen (Tylenol)[5]

Combination Therapies

Elotuzumab is often used in combination with other drugs to enhance its effectiveness. Some common combinations include:

  • Elotuzumab with lenalidomide and dexamethasone[1]
  • Elotuzumab with pomalidomide and dexamethasone[4]
  • Elotuzumab with carfilzomib, lenalidomide, and dexamethasone[6]
  • Elotuzumab with bortezomib[7]

These combinations are designed to attack multiple myeloma cells in different ways, potentially improving the overall effectiveness of the treatment.

Current Clinical Trials

Several clinical trials are currently underway to further investigate the effectiveness of elotuzumab in various treatment scenarios. Some notable trials include:

  • A study comparing elotuzumab monotherapy to other combination therapies in relapsed/refractory multiple myeloma[4]
  • A trial examining elotuzumab in combination with pomalidomide as maintenance therapy after a second autologous stem cell transplant[8]
  • A study investigating the combination of elotuzumab with belantamab mafodotin, another targeted therapy for multiple myeloma[3]

Potential Side Effects

Like all medications, elotuzumab can cause side effects. Common side effects may include:

  • Fatigue
  • Diarrhea
  • Fever
  • Constipation
  • Cough
  • Muscle spasms

More serious side effects, although less common, can include infusion reactions and an increased risk of infections. It’s important to discuss potential side effects with your healthcare provider[1].

Aspect Details
Drug Name Elotuzumab (also known as HuLuc63, Empliciti)
Type of Drug Humanized monoclonal antibody targeting SLAMF7
Target Disease Multiple Myeloma (relapsed/refractory)
Common Combinations Lenalidomide, Pomalidomide, Bortezomib, Dexamethasone
Administration Intravenous infusion
Dosing Schedules Varies by trial; often weekly in initial cycles, then less frequent
Key Outcomes Measured Progression-free survival, Overall response rate, Overall survival
Special Populations Elderly patients, Post-transplant patients
Novel Approaches Combination with other antibodies, Use in maintenance therapy

FAQ

  • What is elotuzumab? Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 protein found on myeloma cells and natural killer cells. It is designed to enhance the immune system's ability to attack and kill myeloma cells.
  • How is elotuzumab administered? Elotuzumab is typically administered intravenously (IV). The dosing schedule varies depending on the specific trial, but it often involves weekly doses during initial cycles, followed by less frequent dosing in later cycles.
  • What are the common combinations being studied with elotuzumab? Clinical trials are exploring elotuzumab in combination with other drugs such as lenalidomide, pomalidomide, bortezomib, and dexamethasone. These combinations aim to enhance the overall effectiveness of treatment for multiple myeloma.
  • What are the potential side effects of elotuzumab? While side effects can vary, some trials report infusion-related reactions, fatigue, and changes in blood cell counts. Specific side effects depend on the combination of drugs used and are closely monitored during the trials.
  • Who is eligible for these clinical trials? Eligibility criteria vary by trial, but generally include adult patients with relapsed or refractory multiple myeloma who have received one or more prior lines of therapy. Some trials focus on specific patient populations, such as elderly patients or those undergoing stem cell transplantation.

Ongoing Clinical Trials on Elotuzumab

  • Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Croatia Czechia Denmark Finland France +10

  • A study of Cesnicabtagene autoleucel compared to a drug combination for patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Continuing Elotuzumab Treatment for Patients with Multiple Myeloma from Previous Trials

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Romania

  • Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany

  • Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +8

  • Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study Comparing bb2121 with Standard Treatments for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Norway +1

  • Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Denmark France Germany Greece Italy Spain

  • Study Comparing Linvoseltamab to Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Elotuzumab is a monoclonal antibody designed to target specific proteins on myeloma cells.
  • SLAMF7: A protein found on the surface of myeloma cells and natural killer cells. Elotuzumab targets this protein to help the immune system identify and attack myeloma cells.
  • Relapsed Multiple Myeloma: When the disease returns after a period of improvement following treatment.
  • Refractory Multiple Myeloma: When the disease does not respond to treatment or stops responding after initial improvement.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Autologous Stem Cell Transplantation (ASCT): A procedure where a patient's own stem cells are collected, stored, and then given back after high-dose chemotherapy to help restore the bone marrow.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment, which can only be detected by highly sensitive tests.
  • Immunomodulatory Drugs (IMiDs): A class of drugs that modify the immune system's response, such as lenalidomide and pomalidomide, often used in combination with elotuzumab in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT03411031
  2. https://clinicaltrials.gov/study/NCT00425347
  3. https://clinicaltrials.gov/study/NCT05002816
  4. https://clinicaltrials.eu/trial/study-comparing-elranatamab-to-drug-combinations-for-patients-with-relapsed-refractory-multiple-myeloma-after-anti-cd38-therapy/
  5. https://clinicaltrials.gov/study/NCT02541643
  6. https://clinicaltrials.gov/study/NCT03361306
  7. https://clinicaltrials.gov/study/NCT00726869
  8. https://clinicaltrials.gov/study/NCT04584307